Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boryung Pharmaceutical Co., Ltd
This study will be performed in patients with blood pressure (BP) uncontrolled by existing antihypertensive drugs (including ARB) among hypertensive patients visiting outpatient clinic of medical institutions in Korea. The study enrollment number will be assigned to the subjects who provide a written consent to the use of personal information and meet the inclusion/exclusion criteria. Follow-up will be conducted for 12 weeks in total and prespecified study related data will be collected in the case report form.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provided written consent to the use of personal information after receiving the explanation of the objective, methodology, etc. of this clinical study
Male or female adults ≥ 19 years who are diagnosed with essential hypertension
Receiving outpatient treatment at the time of study enrollment
Patients with hypertension uncontrolled by existing antihypertensive drugs (including ARB) whose antihypertensive regimens decided and scheduled to be changed to ARB monotherapy or ARB-containing combination therapy (the result of the arm with a higher mean BP \[systolic BP preferred\] when measured twice with at least a 2-minute interval in both arms at the medical office on the study enrollment date, will become the reference)
* Definition of uncontrolled hypertension: Target BP (SBP \<140 mmHg and DBP \<90 mmHg) not achieved even after the treatment using the existing antihypertensive drugs for 4 weeks or longer
You may not be if
Patients who were hospitalized or are scheduled to be hospitalized 4 weeks before or after the study enrollment date
Patients with suspected or confirmed secondary hypertension
Pregnant or breast-feeding women
Patients who received investigational product within 12 weeks or are scheduled to participate in another clinical study while participating in this study
Patients who are determined inappropriate for participating in the study by investigators for other reasons
Clareo Health | FimasaRtan-basEd BP Targets After Drug SwitcHing
